Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab for advanced urothelial carcinoma
ChiCTR2000031006Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Jun 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of sintilimab in transitional cell carcinoma (TCC), sponsored by The Second Hospital of Tianjin Medical University. Planned start Jun 2020; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on ChiCTR2000031006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000031006.